|
Indianapolis, Ind. April 16, 2004
Roche Diagnostics Awarded Urinalysis Contract by HealthTrust
Purchasing Group
Agreement broadens access to actionable healthcare information
that is important for people’s well-being
Roche Diagnostics announced today that the company has renewed a
three-year contract with HealthTrust Purchasing Group (HPG) to provide
visual and automated urinalysis products for acute care and alternate
site facilities. The contract is effective May 1, 2004 through April
30, 2007 and has a total value of $3.6 million.
This renewal award includes the CHEMSTRIP® 101, CHEMSTRIP Criterion™
II, CHEMSTRIP® Urine Analyzer and URISYS 2400™ instruments
plus strips and supplies and all visual urinalysis strips and continues
a long-term relationship between HPG and Roche Diagnostics. Roche
Diagnostics currently has contracts with HPG for blood glucose and
blood gas products.
"Our new contract is a testament to our long-term relationship
with HPG, and our urinalysis solutions complement our current portfolio
of blood glucose and blood gas products serving HPG members,"
said Dick Aderman, Senior Vice President and General Manager, Roche
Centralized and Molecular Diagnostics. "Roche Diagnostics is
committed to providing healthcare professionals and their patients
with actionable healthcare information."
HealthTrust Purchasing Group is one of the nation's leading healthcare
group purchasing organizations (GPO) with a current membership in
excess of 1000 facilities and contracting volume totaling more than
$5.5 billion. HPG is committed to providing its customers with the
highest quality, cost-effective supplies and services for their
patients, physicians, nurses and other clinicians. HPG's membership
includes hospitals, surgery centers, clinics, physicians, integrated
delivery networks, and affiliate members. More information about
HPG is available at www.healthtrustpg.com.
About Roche and Roche Diagnostics
Headquartered in Basel, Switzerland, Roche is one of the world's
leading innovation-driven healthcare groups. Its core businesses
are pharmaceuticals and diagnostics. Roche is number one in the
global diagnostics market, the leading supplier of pharmaceuticals
for cancer and a leader in virology and transplantation. As a supplier
of products and services for the prevention, diagnosis and treatment
of disease, the Group contributes on a broad range of fronts to
improving people's health and quality of life. Roche employs roughly
65,000 people in 150 countries. The Group has alliances and research
and development agreements with numerous partners, including majority
ownership interests in Genentech and Chugai. Roche's Diagnostics
Division, the world leader in in-vitro diagnostics with a uniquely
broad product portfolio, supplies a wide array of innovative testing
products and services to researchers, physicians, patients, hospitals
and laboratories world-wide. Roche Diagnostics' North American headquarters
are in Indianapolis, Indiana (www.roche-diagnostics.us).
For further information, please visit our websites www.roche.us
and www.roche-diagnostics.com.
CHEMSTRIP, CHEMSTRIP CRITERION and URISYS 2400 are trademarks of
a Member of the Roche Group.
For additional information contact:
|
